Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Category: CTEGD Blog

Trainee Spotlight: Edwin Pierre Louis

Trainee Edwin Pierre Louis

 

Edwin Pierre Louis is a pre-doctoral trainee in the laboratory of Dr. Drew Etheridge. Originally from Haiti, he immigrated to the US to attend the University of Florida (UF), where he graduated with a Bachelor of Science in Biochemistry Molecular Biology. After earning his degree at UF, Edwin accepted a position as a biological scientist in the UF Center of Excellence for Regenerative Health Biotechnology, with a focus on gene and cell based therapeutic development, where he worked for three years. There, he first discovered his love of host-pathogen interactions as a biological scientist working under the supervision of Dr. Richard Snyder for the component Florida Biologix at this center and later merged to create Brammer Bio which was subsequently acquired by Thermo Fisher Scientific. During this time in industry, he realized that to improve his scientific capacities he would need to continue his studies by pursuing a graduate degree. As part of his preparations to apply to a graduate program, he joined the UGA post-baccalaureate PREP program whose mission is to prepare students interested in a graduate degree for the application process. During this time, he was granted the opportunity to join Dr. Michael Terns’ laboratory for a year where he investigated the molecular mechanism of CRISPR-Cas based viral defense in Streptococcus thermophilus as well as prime adaptation events in the type II-A CRISPR-Cas system.

Since attending UGA, Edwin has been awarded both the Gateway to Graduate School Bridge Program and the Graduate Scholars Leadership, Engagement and Development Program (GS LEAD) scholarships sponsored by the National Science Foundation (NSF).

What is your research focus and why are you interested in the topic?

Broadly, my key research interests center around how organisms like viruses and parasites manipulate their host cell in order to grow and propagate. My current project is focused on elucidating how the protozoan pathogen Toxoplasma gondii is able to use secreted protein effectors to manipulate its host cells functions.

Why did you choose UGA?

I chose to study at the University of Georgia, in part, because of my excellent post-baccalaureate experience in the PREP program. It was evident from my interactions that UGA excels at fostering a productive relationship between students and faculty. Regardless of any faculty member’s relationship to the students, there was a sustained willingness for faculty to give of their time in order to see the students succeed.  I also decided to pursue my PhD at UGA because of the cutting-edge research and in particular the collection of outstanding parasitologists that is uniquely found in the Center for Tropical and Emerging Global Diseases (CTEGD).

What are your future professional plans?

As I continue my graduate studies on host pathogen interaction, I plan to do some post-doctoral trainings to augment my apprenticeship and ultimately become an independent scientist to lead my own research group.  I also hope to be able to give back to the local community that has contributed so much to my own personal success by donating my time and knowledge to mentor young budding scientists especially those from underprivileged homes and/or underdeveloped countries.

 

Support trainees like Edwin by giving today to the Center for Tropical & Emerging Global Diseases.

[button size=’large’ style=” text=’Give Online’ icon=” icon_color=’#b80d32′ link=’https://ctegd.uga.edu/give/’ target=’_self’ color=” hover_color=” border_color=” hover_border_color=” background_color=” hover_background_color=” font_style=” font_weight=” text_align=’center’ margin=”]

Battling Malaria

UGA is developing new drugs to fight a lethal parasite. Dennis Kyle discusses what his lab is doing to fight malaria in this brief (2:30) video.

 

HELP BATTLE DEADLY DISEASES

Donate to the Center for Tropical and Emerging Global Diseases

[button size=’large’ style=” text=’Give Now’ icon=” icon_color=’BA0C2F’ link=’https://gail.uga.edu/commit?cat=campus&subcat=research&des=91700000′ target=’_self’ color=” hover_color=” border_color=” hover_border_color=” background_color=” hover_background_color=” font_style=” font_weight=” text_align=” margin=”]

Sharing the Knowledge: NIH Award Supports Expanded Genomics Data Resource

By: Alan Flurry

A team led by scientists at the University of Pennsylvania and University of Georgia provides thousands of researchers around the world with access to the Eukaryotic Pathogen Genomics Database (EuPathDB.org), a collection of resources for analyzing large-scale datasets associated with microbial pathogens. These include the parasites responsible for malaria, sleeping sickness, and toxoplasmosis; the fungi responsible for thrush, aspergillosis and Valley Fever; and many other important diseases. In parallel, a team led by investigators at the University of Notre Dame has been responsible for similar resources covering invertebrate vectors of disease (VectorBase.org), including the mosquitoes transmitting malaria, Zika, and yellow fever, the ticks responsible for Lyme disease and Rocky Mountain Spotted Fever, and others.

To ensure that this important work continues, the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, has awarded a new contract to integrate these resources, worth up to $7.2 million in 2019-2020. The five‐year award for this project, rebranded as VEuPathDB.org (The Eukaryotic Pathogen, Host & Vector Genomics Resource) could total as much as $38.4 million if all associated options are exercised.

The patterns revealed by such “Big Data” provide insight into important diseases, permit the development of diagnostic methods, and define drug and vaccine targets. But to be useful, these immense datasets must be sensibly organized and made conveniently accessible to the researchers worldwide. The integrated VEuPathDB database hosts data on thousands of genomes, representing hundreds of species, along with extensive information on isolate provenance, gene function and the like.

The award is based at Penn, and directed by David S Roos, E Otis Kendall Professor of Biology in the School of Arts & Sciences. Key subcontracts include the University of Georgia (Joint PI Jessica C. Kissinger, Distinguished Professor of Genetics and Bioinformatics in the Franklin College of Arts and Sciences and the Center for Tropical and Emerging Global Diseases), University of Notre Dame (Joint PI Mary Ann McDowell, Associate Professor of Biological Sciences at the Eck Institute for Global Health).  Additional co-investigators include Professors Christian Stoeckert of Penn’s Perelman School of Medicine, Mark Caddick of the University of Liverpool, George K Christophides of Imperial College London, and Paul Flicek, Associate Director of the EMBL-EBI (European Bioinformatics Institute).

“It is wonderful to see the continued investment by NIH, the Wellcome Trust and others in resources that make performing much needed global research on infectious diseases both easier and better,” Kissinger said. “Datasets are larger and more complex than ever due to significant advances in technology. These breakthroughs create challenges for making the resulting data truly accessible and usable by the average researcher.  We strive to remove barriers, integrate diverse data and accelerate the speed with which new hypotheses can be generated and ideas tested both in silico and in the lab.”

“A critical aspect of this now joint program will be its accessibility throughout the world, empowering any infectious disease investigator to interrogate these highly complex databases in comprehensible and productive ways,” said Dan Colley, UGA professor of microbiology and member of the CTEGD who has conducted extensive research on n schistosomiasis in western Kenya. “These databases have led, and the merged data base will lead, to the design of new drugs and studies on how to better control and eliminate these major public health challenges, such as malaria, toxoplasmosis, yellow fever, eastern equine encephalitis and Lyme disease.”

“Since its conception, corresponding with the release of the first parasite genomes, EuPathDB has been a transformative tool in our search for a better understanding of human disease and parasite biology,” said Stephen Hadjuk, Professor Emeritus of biochemistry & molecular biology at UGA whose lab investigates trypanosomes, the causative agent of an human African sleeping sickness. “Today, it’s difficult to imagine any serious research on parasites and host pathology that doesn’t rely, at least to some extent, on EuPathDB. The decision to incorporate the vectors database into the eukaryotic pathogens database was brilliant, and makes this is an exciting new chapter in the EuPathDB story.”

“Innumerable investigators, including my own laboratory, rely on daily access to the high quality genomic and functional datasets made available by the VEuPathDB Project,” says Keith Gull, Professor of Molecular Microbiology at Oxford University.  “Sustainable support for such resources is imperative if we are to capitalize on the promise of modern technologies for scientific discovery and translational application.”  Joe Heitman, James B Duke Professor / Chair of Molecular Genetics & Microbiology at Duke University agrees: “Inclusion of fungal pathogens under the BRC umbrella has greatly enhanced our ability to study important human mycoses.  Cross-species comparisons provide insights into the biology and pathogenesis of these fascinating organisms, which can be deadly – but can also serve as workhorses for valuable biotechnology development.”

Originally published at https://www.franklin.uga.edu/news/stories/2019/sharing-knowledge-nih-award-supports-expanded-genomics-data-resource

Clinically silent relapsing malaria may still pose a threat

The immune system can control a relapsing form of malaria enough to avoid clinical signs of disease, but it doesn’t eliminate transmissible parasites from the body that may still be infectious to mosquitoes. That’s the conclusion of a study on a nonhuman primate model of Plasmodium vivax infection, which has implications relevant to malaria elimination strategies.

Keep reading about the MaPHIC study at Technology.org

Visiting Scholar Fellow: Fernando Sanchez-Valdéz

Fellow: Fernando Sanchez ValdezDr. Fernando Sanchez-Valdéz, from Salta, Argentina, completed a Ph.D. in Molecular Biology at the Faculty of Pharmacy and Biochemistry at the University of Buenos Aires, Argentina in 2014. After his Ph.D., he completed a postdoctoral fellowship in Dr. Rick Tarleton´s laboratory at University of Georgia. In 2018, he obtained a Research Scientist position in the career pathway of the National Research Council in Argentina (CONICET). Earlier this year, he was awarded a fellowship from the CTEGD-Janssen Visiting Scholars Program, which enabled him to return to the Tarleton Research Group.

What is your primary research focus? Why are you interested in this subject?

The main focus of my research has been to uncover the mechanism of drug resistance in the Chagas disease agent, Trypanosoma cruzi. The main question we are trying to answer is why the treatment with highly effective drugs like Benznidazole (the current available treatment for Chagas disease) often fails to cure Chagas disease. By combining ex vivo luminescence assays and tissue-clearing techniques we were able to report, for the first time, the presence of dormant non-replicating amastigotes forms in the chronic phase of the disease. Dormant amastigotes were uniquely resistant to extended drug treatment in vivo and in vitro and could re-establish a flourishing infection after treatment interruption. T. cruzi‘s capacity to become dormant makes them transiently drug-resistant, suggesting that this phenomenon accounts for the failure of the otherwise highly active compounds such Benznidazole (Sanchez-Valdéz, et al eLife 2018).

Why did you choose UGA?

I returned to Athens in February 2019 to continue working on the findings we made during my postdoctoral training in the Tarleton Laboratory. I initially decided to come UGA based on a colleague’s recommendations and the fact that Tarleton´s lab is one of the reference centers for Chagas disease research. It’s a really motivating environment to do science since the scientific and technical level here is really high as well as diverse including areas as immunology, drug discovery, genetic manipulation, genomics, diagnostics, etc. Also the amount of resources available is impressive not only from the lab but also from the Biomedical Microscopy Core, Cytometry Shared Resource Laboratory and the animal facility at UGA.

What has been your research project while at UGA?

Currently, we are expanding our knowledge about T. cruzi dormancy and trying to interfere T. cruzi dormancy using new compounds or the conventional drugs but in a different treatment schedule. One of the approaches we are testing now involves the evaluation of drug doses and treatment schemes able to kill dormant parasites. For this purpose, we are optimizing a robust platform to detect low levels of parasites in whole clarified mice organs using light-sheet fluorescent microscopy. This technique will allow us the specific detection of low levels of persistent dormant parasites.

How has the CTEGD-Janssen Visiting Scholar Fellowship and your time at UGA impacted your research and professional goals?

I am so glad about the opportunity to continue working on T. cruzi dormancy with such experienced and renowned scientists and particularly using state-of-the-art microscopy techniques currently unavailable in South America. This experience will definitely have a positive impact on my career development and probably in the Chagas disease research field.